A pilot randomized controlled trial of a multicomponent intervention to improve sexual function in female breast cancer survivors
This study demonstrates that a multicomponent approach combining hypnotic relaxation and a vaginal moisturizer can feasibly improve sexual function, body image, and GSM symptoms in breast cancer survivors.
This 2‑arm pilot randomized controlled trial evaluated an 8‑week self‑administered multicomponent intervention comprising hypnotic relaxation (HRI) plus vaginal moisturizer versus vaginal moisturizer alone (VMO) for improving genitourinary syndrome of menopause (GSM), sexual desire, and body image among female breast cancer survivors. Thirty participants (age 55 ± 10 yr) were randomized 1:1; adherence was ≥90% for both interventions. Both groups showed large improvements in FSFI lubrication (Cohen d = 1.50) and pain (d = 0.81). Compared with VMO, HRI yielded a small but favorable effect on interest (d = 0.37) and a moderate effect on body image (d = 0.42). Feasibility benchmarks for accrual, retention, and adherence were met. The study suggests that adding hypnotic relaxation to vaginal moisturizer is feasible and may enhance body image and sexual interest in breast cancer survivors, warranting larger trials.
The findings highlight a novel, non‑pharmacologic strategy that addresses both psychological and biological contributors to sexual dysfunction in breast cancer survivors, an area that remains inadequately treated with conventional interventions.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC